Clinical trials: Proteinuria
Renal Disease
A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices…
- Trial name
- NCT05967806
- Testing
- assessment
- Where
- 80 sites in United States, Argentina and 12 more
- Volunteers
- 2,575 people
- Sponsor
- AstraZeneca
C3 Glomerulopathy, Complement-mediated Kidney Disease
CHART-C3G/CLNP023B12011
This is a non-interventional chart abstraction cohort study with longitudinal follow up. Patients with C3G treated with iptacopan will be enrolled and characterized (i.e., systematically describe and summarize) regarding their…
- Conditions
- C3 Glomerulopathy, Complement-mediated Kidney Disease, Proteinuria
- Trial name
- NCT07331259
- Testing
- Iptacopan
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus, Albuminuria
NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
Primary objective: To characterize the effects of 12 weeks treatment with study drug on albumin-creatinine ratio (ACR) in patients with type 2 diabetes and albuminuria Secondary objectives: To characterize the effect of study…
- Trial name
- NCT01547897
- Testing
- NOX-E36
- Where
- 24 sites in Czechia, Germany and 3 more
- Volunteers
- 76 people
- Sponsor
- TME Pharma AG